STOCK TITAN

Zymeworks to Host Second Quarter Results Conference Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Zymeworks Inc. (NYSE: ZYME) is set to report its second quarter 2022 financial results after market close on August 4, 2022. A conference call and webcast will follow at 4:30 p.m. ET to discuss the financial outcomes and provide a corporate update. Zymeworks specializes in developing multifunctional biotherapeutics, with lead candidate zanidatamab currently undergoing multiple clinical trials for HER2-expressing solid tumors. The company is also advancing ZW49, a bispecific HER2-targeted antibody-drug conjugate in Phase 1 development.

Positive
  • Lead candidate zanidatamab in multiple Phase 1, Phase 2, and pivotal clinical trials.
  • Progress in developing ZW49, a bispecific HER2-targeted antibody-drug conjugate.
Negative
  • None.

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its second quarter 2022 financial results after market close on August 4th, 2022. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 4th, 2022 at 4:30 p.m. ET.

Conference Call and Webcast Information

The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2 ‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

Jack Spinks

(604) 678-1388

ir@zymeworks.com



Media Inquiries:

Diana Papove

(604) 678-1388

media@zymeworks.com

Source: Zymeworks Inc.

FAQ

When will Zymeworks announce its Q2 2022 financial results?

Zymeworks will announce its Q2 2022 financial results on August 4, 2022.

What time is the conference call for Zymeworks' Q2 2022 results?

The conference call will take place at 4:30 p.m. ET on August 4, 2022.

What is Zymeworks' lead clinical candidate?

Zymeworks' lead clinical candidate is zanidatamab, a HER2-targeted bispecific antibody.

What is the status of ZW49?

ZW49 is currently in Phase 1 clinical development.

Zymeworks Inc.

NASDAQ:ZYME

ZYME Rankings

ZYME Latest News

ZYME Stock Data

973.93M
66.64M
0.08%
101.32%
6.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MIDDLETOWN